JUST IN • MarketWatch.com - Top Stories
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
READ ORIGINAL REPORT ↗THIS JUST HAPPENED PACKAGES THE WORLD INTO A FAST LIVE FEED SOURCE REPORTING STAYS ONE CLICK AWAY
